Static Cold Storage Segment, by Application to Account Largest Share in Organ Preservation Solutions Market during 2023-2031

According to our latest study on "Organ Preservation Solutions Market Forecast to 2031 -Global Analysis - Product, Organ Type, Application, and End User," the market was valued at US$ 274.41 million in 2023 to US$ 512.62 million by 2031; it is anticipated to record a CAGR of 8.2% from 2023 to 2031. The report highlights the key factors driving the organ preservation solutions market growth and prominent players with their developments in the market.

The Organ preservation solutions market analysis has been carried out by considering the following segments: product, organ type, application, and end user, and geography.

Based on product, the organ preservation solution market is segmented into University of Wisconsin Solution, Custodiol HTK, Perfadex, Hypothermosol, and Others. The University of Wisconsin Solution segment held the largest organ preservation solution market share in 2023. The UW solution is the most commonly used cold storage solution, which has been shown to have increased early pancreas graft function and decreased the incidence of preservation pancreatitis. As mentioned in an article published by the Experimental and Clinical Transplantation in June 2021, the UW solution is a gold standard solution widely used to preserve abdominal organs such as the pancreas due to its greater effectiveness in cold storage. In addition, UW-gluconate, a modified version, is used in experimental perfusion machines.

By organ type, the organ preservation solutions market is segmented into kidneys, liver, lungs, heart, and others. The kidneys segment held the largest market share in 2023. According to the Centers for Disease Control and Prevention (CDC) report published in 2021, more than 15% (1 in 7 or ~ 37 million) people in the US suffer from chronic kidney disease each year, with nearly 786,000 suffering from end-stage renal disease (ESRD). Various awareness campaigns are conducted to promote the benefits of kidney transplantation. For instance, in September 2022, the University Health Network's (UHN) Ajmera Transplant Centre announced the launch of a new campaign-Great Actions Leave a Mark-which showcased the stories and scars of 39 living organ donors and transplant recipients across Canada.

By application, the market is segmented into static cold storage, hypothermic machine perfusion, normothermic machine perfusion, and others. The static cold storage segment held the largest organ preservation solution market share in 2023. Static cold storage (SCS) is a recognized method in which the kidney is kept on ice following removal from the donor, and it is subsequently withdrawn from the ice box at the time of implantation. The preservation solution for the cold storage of transplanted kidneys is an ongoing topic of research. A study published in May 2020 in the American Journal of Transplantation assessed the effects of 5 preservation solutions for static cold storage on kidney transplant outcomes using data from the French national transplant registry maintained from 2010 to 2014. The article stated that the number of organs transplanted after undergoing static cold storage remains high, making up 58% of kidney transplants from donors after brain death (DBD) in France in 2018.

Based on end user, the organ preservation solutions market is segmented into organ transplant centers, hospitals, and specialty clinics. The organ transplant centers segment dominated the market in 2023. Transplant centers are healthcare facilities that are supervised and equipped to perform complex organ transplantation procedures; some of them also have a blood or marrow transplant program. Transplant centers are members of the Organ Procurement and Transplant Network (OPTN) and must meet requirements stated by the government. The US has more than 250 transplant centers, and 4 of these are functional in the service area covered by the Donor Alliance, a nonprofit organ procurement organization. All transplantation centers are connected with a parent hospital, hospital system, or university that compete with each other for organ procurement.

The scope of the Organ preservation solutions market report covers North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, Japan, India, Australia, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the biggest contributor to the global Organ preservation solutions market. Asia Pacific is predicted to show the highest CAGR in the market during 2023-2031. The market growth in the APAC region is attributed to the growing number of organ transplantations across several countries in the region, increasing aging population, rising prevalence of chronic diseases that lead to organ failure, and increasing developments and improvements in organ preservation solutions.

Waters Medical Systems LLC, XVIVO Perfusion, TransMedics, OrganOx Limited, Paragonix Technologies, Inc, Dr. Franz Koehler Chemie GmbH, Accord Healthcare, ST CENTURY MEDICINE, Shanghai Genext Pharmaceutical Technology, and Bridge to Life Ltd are among the leading companies operating in the global organ preservation solutions market.

Companies operating in the organ preservation solutions market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the organ preservation solutions market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the developments made by the companies operating in organ preservation solutions market are as follows:

- In February 2024, Bridge to Life reintroduced EasiSlush to the US market, meeting high demand for easy-to-use sterile slush for organ transplantation. EasiSlush is renowned for its ease of use, high quality, and portability, making it the preferred choice for organ transplant professionals.

- In December 2021, Bridge to Life, Ltd. received FDA approval for its VitaSmart Liver Machine Perfusion System. The company plans to start its US pivotal Bridge to HOPE Liver Clinical Trial by the end of 2021. The trial will compare cold storage to cold storage followed by hypothermic oxygenated perfusion using the VitaSmart system. It aims to enroll up to 244 patients and involve up to 15 hospitals.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com